The Cancer Treatment by Using Liposome as Drug Delivery Systems and Its Applications: An Extensive Review
Cancer is a leading cause of death in many countries around the world. However, the efficacy of current standard treatments for a variety of cancers is suboptimal. In the development of cancer chemotherapy, besides the discovery of new anticancer drugs, a variety of nanocarrier systems for the delivery of previously developed and new chemotherapeutic drugs have currently been explored. Liposome is one of the most studied nanocarrier systems because of its biodegradability, simple preparation method, high efficacy and low toxicity. To make the best use of this vehicle, a number of multifunctionalized liposomal formulations have been investigated. This review will be including the development of liposomes for cancer therapy, liposomal formulation of various anticancer drugs that are commercially available, recent progress in liposome technology for the treatment of cancer, and the next generation of lipid-based nanoparticles., recent progress in liposome technology for the treatment of cancer, and the next generation of lipid-based nanoparticles.
2. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of molecular biology. 1965;13(1):238-52.
3. Gupta PK, Jaiswal AK, Kumar V, Verma A, Dwivedi P, Dube A, et al. Covalent functionalized self-assembled lipo-polymerosome bearing amphotericin B for better management of leishmaniasis and its toxicity evaluation. Molecular pharmaceutics. 2014;11(3):951-63.
4. Rieder AA, Koller D, Lohner K, Pabst G. Optimizing rapid solvent exchange preparation of multilamellar vesicles. Chemistry and physics of lipids. 2015;186:39-44.
5. Bhatia T, Husen P, Brewer J, Bagatolli LA, Hansen PL, Ipsen JH, et al. Preparing giant unilamellar vesicles (GUVs) of complex lipid mixtures on demand: Mixing small unilamellar vesicles of compositionally heterogeneous mixtures. Biochimica et biophysica acta. 2015;1848(12):3175-80.
6. Karamdad K, Law RV, Seddon JM, Brooks NJ, Ces O. Preparation and mechanical characterisation of giant unilamellar vesicles by a microfluidic method. Lab on a chip. 2015;15(2):557-62.
7. Sweeney AE. Nanomedicine concepts in the general medical curriculum: initiating a discussion. Int J Nanomedicine. 2015;10:7319-31.
8. Safari J, Zarnegar Z. Advanced drug delivery systems: Nanotechnology of health design A review. Journal of Saudi Chemical Society. 2014;18(2):85-99.
9. Yun YH, Lee BK, Park K. Controlled Drug Delivery: Historical perspective for the next generation. J Control Release. 2015;219:2-7.
10. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. International Journal of Pharmaceutics. 2018;536(1):95-107.
11. Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved <em>in vitro</em> efficacy on ovarian cancer cells. Cancer Research. 2016;76(14 Supplement):2065.
12. Vhora I, Lalani R, Bhatt P, Patil S, Patel H, Patel V, et al. Colloidally Stable Small Unilamellar Stearyl Amine Lipoplexes for Effective BMP-9 Gene Delivery to Stem Cells for Osteogenic Differentiation. 2018.
13. Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, et al. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. Journal of Drug Delivery Science and Technology. 2018;45:334-45.
14. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. J Control Release. 2016;226:148-67.
15. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews. 2013;65(1):36-48.
16. Sutradhar KB, Amin ML. Nanotechnology in Cancer Drug Delivery and Selective Targeting. ISRN Nanotechnology. 2014;2014:939378.
17. James ND, Coker RJ, Tomlinson D, Harris JR, Gompels M, Pinching AJ, et al. Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clinical oncology (Royal College of Radiologists (Great Britain)). 1994;6(5):294-6.
18. Barenholz Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-34.
19. Patel P, Hanini A, Shah A, Patel D, Patel S, Bhatt P, et al. Surface Modification of Nanoparticles for Targeted Drug Delivery. In: Pathak YV, editor. Surface Modification of Nanoparticles for Targeted Drug Delivery. Cham: Springer International Publishing; 2019. p. 19-31.
20. Berger D, Grieshop K, Lind M, Goenaga J, Maklakov A, Arnqvist G. Berger et al. 2014 (IaSC and environmental stress). 2014.
21. Chou H, Lin H, Liu JM. A tale of the two PEGylated liposomal doxorubicins. Onco Targets Ther. 2015;8:1719-20.
22. Fantini M, Gianni L, Santelmo C, Drudi F, Castellani C, Affatato A, et al. Lipoplatin treatment in lung and breast cancer. Chemother Res Pract. 2011;2011:125192-.
23. Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2008;3(6 Suppl 2):S164-70.
24. Broglio KR, Stivers DN, Berry DA. Predicting clinical trial results based on announcements of interim analyses. Trials. 2014;15:73.
25. Fantini M, Gianni L, Santelmo C, Drudi F, Castellani C, Affatato A, et al. Lipoplatin Treatment in Lung and Breast Cancer. Chemother Res Pract. 2011;2011:125192.
26. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future oncology (London, England). 2011;7(8):937-45.
27. Staruch R, Chopra R, Hynynen K. Localised drug release using MRI-controlled focused ultrasound hyperthermia. International journal of hyperthermia: the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2011;27(2):156-71.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Innovative Science & Technology affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJIST.
Download link for COPYRIGHT FORM